Trade Genfit SA - GNFTfr CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.09 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.017257% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | -0.004965% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | EUR | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | France | ||||||||
| Commission on trade | 0% |
| Prev. Close | 3.1 |
| Open | 3.16 |
| 1-Year Change | -0.32% |
| Day's Range | 3.14 - 3.22 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2025 | 3.20 | 0.09 | 2.89% | 3.11 | 3.22 | 3.11 |
| Apr 23, 2025 | 3.10 | 0.07 | 2.31% | 3.03 | 3.19 | 3.03 |
| Apr 22, 2025 | 2.99 | -0.03 | -0.99% | 3.02 | 3.09 | 2.99 |
| Apr 17, 2025 | 3.01 | -0.10 | -3.22% | 3.11 | 3.11 | 3.01 |
| Apr 16, 2025 | 3.05 | -0.04 | -1.29% | 3.09 | 3.16 | 3.03 |
| Apr 15, 2025 | 3.09 | 0.06 | 1.98% | 3.03 | 3.16 | 3.02 |
| Apr 14, 2025 | 3.03 | 0.08 | 2.71% | 2.95 | 3.10 | 2.95 |
| Apr 11, 2025 | 2.98 | 0.09 | 3.11% | 2.89 | 3.00 | 2.89 |
| Apr 10, 2025 | 2.86 | -0.32 | -10.06% | 3.18 | 3.18 | 2.86 |
| Apr 9, 2025 | 2.89 | -0.19 | -6.17% | 3.08 | 3.08 | 2.89 |
| Apr 8, 2025 | 3.08 | 0.05 | 1.65% | 3.03 | 3.24 | 3.03 |
| Apr 7, 2025 | 2.96 | 0.12 | 4.23% | 2.84 | 3.08 | 2.74 |
| Apr 4, 2025 | 3.09 | -0.10 | -3.13% | 3.19 | 3.23 | 3.02 |
| Apr 3, 2025 | 3.22 | 0.07 | 2.22% | 3.15 | 3.28 | 3.15 |
| Apr 2, 2025 | 3.25 | 0.03 | 0.93% | 3.22 | 3.26 | 3.17 |
| Apr 1, 2025 | 3.27 | 0.04 | 1.24% | 3.23 | 3.37 | 3.22 |
| Mar 31, 2025 | 3.22 | -0.04 | -1.23% | 3.26 | 3.32 | 3.22 |
| Mar 28, 2025 | 3.31 | 0.06 | 1.85% | 3.25 | 3.43 | 3.25 |
| Mar 27, 2025 | 3.31 | 0.06 | 1.85% | 3.25 | 3.45 | 3.25 |
| Mar 26, 2025 | 3.25 | -0.01 | -0.31% | 3.26 | 3.33 | 3.25 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Genfit Company profile
About Genfit SA
Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The Company targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.
Financial summary
BRIEF: For the six months ended 30 June 2021, Genfit SA revenues decreased 42% to EUR3.4M. Net income totaled EUR9.1M vs. loss of EUR53M. Revenues reflect Public Financing of research expenditure decrease of 38% to EUR3.2M, Other Operating Income decrease of 66% to EUR174K, Revenue decrease of 91% to EUR11K. Net Income reflects R&D Subcontractors decrease of 38% to EUR15M (expense).
Equity composition
01/2014, Rights Issue, 1 new share for every 33 shares held @ EUR6.98 (Factor: 1.00937).10/2016, Rights Issue, 1 new share for every 9 shares held @ EUR14.3 (Factor: 1.09242).
| Industry: | Biotechnology & Medical Research (NEC) |
Parc Eurasanté 885 avenue Eugène Avinée
LOOS
HAUTS-DE-FRANCE 59120
FR
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com